Grants for Special district governments - Health

This funding opportunity provides financial support for small-scale cancer research projects that can be completed quickly, targeting a wide range of organizations, including universities, nonprofits, and businesses, to advance cancer prevention, diagnosis, and treatment.

This funding opportunity supports early career researchers in the U.S. to conduct exploratory studies in areas related to hearing, communication, and sensory disorders, helping them gather preliminary data for future larger grant applications.

The TMD Collaborative for Improving Patient-Centered Translational Research (TMD IMPACT) grant aims to establish a national research collaborative to advance the understanding, diagnosis, treatment, and care of Temporomandibular Disorders (TMD) through interdisciplinary research and community engagement.

The National Institutes of Health (NIH) has announced a funding opportunity titled Co-infection and Cancer (R01 Clinical Trial Not Allowed) under Funding Opportunity Number PAR-25-082. This initiative, led by the National Cancer Institute (NCI), is aimed at advancing research into the roles of co-infection in cancer development and progression. Co-infection is defined as the occurrence of two or more infections, whether simultaneous or sequential, involving pathogens or non-pathogenic agents, including viruses, bacteria, and parasites. The goal of this program is to explore how these co-infections contribute to cancer risk and progression and identify potential strategies for cancer prevention and treatment. The program encourages investigations that focus on co-infections with known oncogenic agents, excluding human immunodeficiency virus (HIV), and seeks studies that can lead to new opportunities in cancer treatment and prevention. In addition to pathogenic agents, research that includes the role of non-pathogenic agents, such as those in the microbiome, will be considered responsive. The program supports projects that delve into uncharted areas of co-infection and cancer, with an emphasis on mechanistic and epidemiologic research that could have practical implications for cancer control. Applicants are encouraged to focus on differences in cancer susceptibility, progression, and survival among diverse populations, including those that are racially or ethnically diverse, as well as medically underserved communities. International collaborations are also supported, particularly for studies in low- and middle-income countries where infection-associated cancers are more prevalent. The first submission date is January 5, 2025, with application due dates beginning on February 5, 2025. Budgets are not limited but must align with the scope of the project, and the maximum project period is five years. Applications must be submitted electronically through NIH's ASSIST system or Grants.gov. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, and foreign entities. The program seeks to support well-developed research projects backed by preliminary data. Studies that focus solely on co-infection with HIV or involve only a single pathogen will not be considered responsive. Evaluation criteria include the scientific merit of the project, innovation, and feasibility, as well as the expertise of the research team. This funding opportunity offers a unique chance to explore how co-infections contribute to cancer and potentially uncover new strategies for prevention and treatment across diverse populations.

Grant Title: Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional) aims to support research on the neurological and mental health impacts of chronic illnesses triggered by infections, such as post-COVID conditions and myalgic encephalomyelitis, focusing on their underlying mechanisms and potential treatments.

This funding opportunity provides financial support for innovative research projects aimed at understanding the neurological and mental health effects of chronic illnesses linked to infections, such as Long COVID and chronic fatigue syndrome, encouraging studies that explore their underlying mechanisms.

Grant Title: Centers on the Demography and Economics of Aging, Including Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) (D and E Centers) (P30 Clinical Trial Optional) aims to support interdisciplinary research centers that focus on the social science aspects of aging, particularly related to health disparities, economic impacts, and caregiving for dementia, while fostering collaboration among diverse scholars and institutions.

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed) aims to support the clinical validation of already analytically validated biomarkers and assays for cancer detection, diagnosis, and treatment monitoring, ensuring they are reliable and ready for use in clinical studies without conducting new trials.

Assay Validation of High Quality Markers for Clinical Studies in Cancer aims to fund the validation of reliable molecular, cellular, or imaging markers for cancer detection, diagnosis, and treatment, ensuring they meet necessary performance standards for use in clinical trials and studies.

Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required) aims to fund a Data Coordinating Center that will manage and analyze data for multi-site clinical trials focused on mind and body interventions, ensuring successful project coordination and compliance with regulatory standards.

Grant Title: Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional) aims to support the development and testing of integrated healthcare models that combine HIV/AIDS, Hepatitis, addiction treatment, and primary care services to improve health outcomes for individuals at risk for or living with these conditions.

Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services aims to fund research that develops and tests innovative models of integrated healthcare to improve outcomes for individuals at high risk for or living with HIV, Hepatitis, and substance use disorders by enhancing service delivery and coordination of care.

Grant Title: New Therapeutic Strategies for Genital Herpes (R21/R33 Clinical Trial Not Allowed) aims to fund innovative research to develop new treatments for genital herpes that can reduce viral shedding, prevent lesions, and lower transmission risks.

This funding opportunity provides up to $1 million to a wide range of organizations to develop a centralized resource for exploring and analyzing single-cell genomics data from the human brain, enhancing research on brain health and disease.

NIA Postdoctoral Fellowship Award to Promote Diversity in Translational Research for AD/ADRD aims to support postdoctoral scientists from diverse backgrounds in developing skills for translational research on Alzheimer's Disease and Related Dementias through mentorship and targeted research experiences.

NIA Predoctoral Fellowship Award to Promote Diversity in Translational Research for AD/ADRD (F31) aims to support and develop promising predoctoral candidates from underrepresented backgrounds in Alzheimer's disease research by providing financial support and mentorship to enhance their skills in data science and drug discovery.

This funding opportunity is designed for researchers with active NCI R01 grants to validate and enhance existing cancer biomarker assays, facilitating their clinical use and improving cancer detection and treatment strategies.

This funding opportunity supports ongoing clinical trials aimed at improving the diagnosis, prevention, and treatment of dental, oral, and craniofacial diseases, encouraging applications from a wide range of eligible institutions and organizations.

The "NCI National Clinical Trials Network - Network Lead Academic Participating Sites" grant is a funding opportunity from the National Cancer Institute for academic centers to provide scientific leadership and patient recruitment for large-scale, multi-institutional cancer clinical trials, with a focus on treatment trials, rare cancers, and underserved populations, offering up to $1.7 million per year for a six-year project period.

This funding opportunity supports U.S. institutions and organizations in developing centers that integrate advanced translational science into cancer clinical trials, enhancing research on precision medicine and rare cancers.